Stay in the know
Receive timely insights and briefings from HSF Kramer, tailored to keep you informed and ahead
Subscribe now
Herbert Smith Freehills Kramer (HSF Kramer) is pleased to be advising CSL on its recently announced proposed demerger of its Seqirus business (Seqirus) as a standalone ASX-listed entity by the end of Financial Year 2026.
Seqirus is one of the world’s largest influenza vaccine providers, dedicated to advancing public health through innovative vaccine solutions and pandemic preparedness.
The HSF Kramer team is led by partners Priscilla Bryans, Baden Furphy, Alexander Mackinnon, and Michael Ziegelaar, with partner Ryan Leslie advising on the tax aspects of the transaction.
Key contacts
Priscilla Bryans
Partner, Melbourne
Baden Furphy
Partner, Melbourne
Alexander Mackinnon
Partner, Melbourne
Michael Ziegelaar
Partner, Melbourne
Ryan Leslie
Partner, Melbourne
Media contact
For further information on this news article, please contact:
Gina Baldassarre
External Communications Manager
Sydney
More news
31 August 2026
Herbert Smith Freehills Kramer advises Sentinel Capital Partners in sale of Revenew International
On August 31, 2026, HSF Kramer client Sentinel Capital Partners announced the sale of Revenew International, a Houston, Texas based professional services …
28 August 2026
Herbert Smith Freehills Kramer advises DigitalBridge on its acquisition of PLUS ES
HSF Kramer is pleased to be advising leading global alternative asset manager, DigitalBridge, on the acquisition of Ausgrid’s PLUS ES contestable smart …
28 August 2026
Herbert Smith Freehills Kramer advises Marubeni Corporation on acquisition of TOLUS Group AG
Leading global law firm Herbert Smith Freehills Kramer has advised Marubeni Corporation on the acquisition of Swiss and Austrian machine tool distributor …